GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.
about
Low protein diets in patients with chronic kidney disease: a bridge between mainstream and complementary-alternative medicines?Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best PracticeGlomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic reviewCigarette smoking and cardio-renal events in patients with atherosclerotic renal artery stenosis.Association between responsiveness to methoxy polyethylene glycol-epoetin beta and renal survival in patients with non-dialysis-dependent chronic kidney disease: a pooled analysis of individual patient-level data from clinical trials.Study of Neutrophil-lymphocyte Ratio as Novel Marker for Diabetic Nephropathy in Type 2 Diabetes.Increased C4 and decreased C3 levels are associated with a poor prognosis in patients with immunoglobulin A nephropathy: a retrospective studyDefining new surrogate markers for CKD progression.Precision renal medicine: a roadmap towards targeted kidney fibrosis therapies.Are Urinary Tubular Injury Markers Useful in Chronic Kidney Disease? A Systematic Review and Meta Analysis.Biomarkers and surrogate endpoints in kidney disease.Urinary uromodulin, kidney function, and cardiovascular disease in elderly adults.Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study.Structural Predictors of Loss of Renal Function in American Indians with Type 2 Diabetes.Effect of Intensive Versus Usual Blood Pressure Control on Kidney Function Among Individuals With Prior Lacunar Stroke: A Post Hoc Analysis of the Secondary Prevention of Small Subcortical Strokes (SPS3) Randomized Trial.Association of short sleep duration and rapid decline in renal function.Measures of Urinary Protein and Albumin in the Prediction of Progression of IgA Nephropathy.Bariatric surgery is associated with improvement in kidney outcomes.Change in Measured GFR Versus eGFR and CKD Outcomes.Severe Decline of Estimated Glomerular Filtration Rate Associates with Progressive Cognitive Deterioration in the Elderly: A Community-Based Cohort Study.Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials.Will the future lie in multitude? A critical appraisal of biomarker panel studies on prediction of diabetic kidney disease progression.Association between Endothelin-1 Levels and Kidney Disease among Blacks.Renal function trajectory over time and adverse clinical outcomes.Acute Declines in Renal Function during Intensive BP Lowering: Implications for Future ESRD Risk.Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease.Association between Soluble Klotho and Change in Kidney Function: The Health Aging and Body Composition Study.Developing Treatments for Chronic Kidney Disease in the 21st Century.The next generation of therapeutics for chronic kidney diseaseEffects of Intensive BP Control in CKD.Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment.Anti-TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy.Patterns of Estimated Glomerular Filtration Rate Decline Leading to End-Stage Renal Disease in Type 1 Diabetes.Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease.Risk of ESRD and Mortality Associated With Change in Filtration Markers.Determinants of decline of renal function in treated hypertensive patients: the Campania Salute Network.Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality.Interstitial fibrosis scored on whole-slide digital imaging of kidney biopsies is a predictor of outcome in proteinuric glomerulopathies.Aortic stiffness and change in glomerular filtration rate and albuminuria in older people.
P2860
Q26743443-2C8A03F8-4928-40CB-B263-72D6DB3516C0Q26767011-696838A2-65D2-474A-9974-EFF63E6652DAQ26822927-C16B2F78-4703-4C7F-8A00-1AFC54B3271BQ30353509-F7FB9EBE-DC08-460F-A1D2-79A80DEF2B6EQ31108646-FE7381BF-9499-4569-8CBA-E8C688381172Q33697462-85C8726A-AE18-4B19-9FE0-E5FE73079220Q33893355-5E8CA183-8CC8-49ED-922B-116D099BBC0FQ34810386-176FB6DD-3245-40DC-9050-68FA03241E97Q36015077-5166F4C3-3BEE-418A-9283-C138517B7A90Q36210315-CC71ED88-7EEB-4A1D-A0D1-A3AF367C1AE9Q36284659-E38E9A46-1FC0-4923-87DB-48E36F16C942Q36299917-CB4F7870-FB66-4CC2-9092-A60BA8ED8280Q36315937-21014564-BF00-4582-A8E8-ECE966BDE985Q36543068-77CC217A-2FAF-4DD2-84FD-B8C322C98BA4Q36791014-858CB983-40A6-462A-9A57-D09917F0A6E1Q36906016-A35E0480-E2F1-4BBD-972C-C0D650867809Q36965109-1A9C1ED8-E2E1-4739-98B2-823CBD1B6041Q37017318-D0F64C20-A392-4482-BAEB-68C879D51567Q37051996-B4DCBCEF-7620-4042-A511-9C82909A7D77Q37648683-F97102F0-E6D2-44AD-9712-F8532F33E2DCQ38372995-7197423D-DAF3-4495-8F12-D8BC8ED48B2DQ38545232-DA0DB716-D20C-4A26-BD0B-4FBD416E1769Q38553935-2200D018-8319-4B89-B3EB-97438BB05DA3Q38658961-30B4E1D5-27E0-4F3F-B6B3-4C546F6DC18AQ38686233-659B768E-4036-4B45-A111-BC65311C6931Q38687593-3735299E-00DC-4BEA-855D-CD59B3B047ABQ38732291-7B02450C-6103-4471-B246-1B66D11D1E5DQ38768281-353794C8-1113-4956-91CD-0EB597946F0CQ38781550-8F73CA1A-B16A-42B2-B89C-992F046BF1E3Q38845590-C1D49B75-84B4-4610-83C7-EDF9BF4E2DCAQ38943637-F713F955-DFA6-49CE-A2E6-542746F4A3A2Q39112475-66395BC2-4DB6-499B-AC20-A46F5A249983Q39372162-336F3CEB-70A0-45BC-BC52-02A59179E43FQ39372179-D72F4B39-4438-4345-B8FB-9C6A9B1554B4Q40060474-10868160-3CBD-4221-8ACF-1E49646B0C45Q40146334-99E1C0D0-49C7-47BE-A056-5A5A0289FE29Q40203629-65B1A655-3944-48F8-83EF-6348BA2E3C2BQ40436912-52E47DC9-8CB2-4FC0-8A4F-7148C961A18EQ40456075-5830BF82-53C5-4BC7-A9FD-FCC970B9162FQ40749134-57B94AA2-954F-4D95-B3C6-EA2F17641610
P2860
GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
GFR decline as an end point fo ...... Food and Drug Administration.
@en
type
label
GFR decline as an end point fo ...... Food and Drug Administration.
@en
prefLabel
GFR decline as an end point fo ...... Food and Drug Administration.
@en
P2093
P1476
GFR decline as an end point fo ...... Food and Drug Administration.
@en
P2093
Alfred K Cheung
Andrew S Levey
Dick de Zeeuw
Edmund Lewis
Kerry Willis
Kunihiro Matsushita
Lesley A Inker
Tom Greene
P304
P356
10.1053/J.AJKD.2014.07.030
P50
P577
2014-10-16T00:00:00Z